A gene therapy for autosomal dominant leukodystrophy.
OligoVale is developing a one-time treatment that lowers LMNB1, the gene whose overexpression drives ADLD, a fatal, ultra-rare disease with no approved therapy.
We exist to bring the first treatment to people living with ADLD.
How OligoVale works
ADLD is caused by too much LMNB1. OligoVale lowers it.
Too much LMNB1
Overexpression of the LMNB1 gene drives demyelination of the central nervous system in ADLD.
Targeted delivery
An oligodendrocyte-targeted AAV carries an RNA-silencing payload to the cells where the disease begins.
LMNB1 lowered
The payload reduces LMNB1 toward normal levels, with the goal of halting progression.
We deliver an RNA-silencing payload through an oligodendrocyte-targeted AAV to reduce LMNB1 toward normal levels in the cells where the disease begins. Our lead candidate is selected and validated in human cells, and is advancing to in vivo and IND-enabling studies.
One program, advancing to the clinic
OV-1 is preclinical: lead candidate selected and validated in human cells, advancing to in vivo and IND-enabling studies.
Team
OligoVale was founded by three scientists and operators committed to bringing the first treatment to people living with ADLD.
Our Scientific Advisory Board will be announced as the company forms.
Careers
We are building a small, focused team. One role is open now.
Lead OligoVale's preclinical program and serve as Principal Investigator on SBIR grants, advancing OV-1 from a validated lead through in vivo and IND-enabling studies.
Demo form; opens your mail app. A connected form ships with the chosen direction.